Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316849 | 0.85 | TRPV4 (0.53) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL29413279 | 0.84 | TRPV4 (0.42) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL51855 | 0.84 | TRPV4 (0.42) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL24872449 | 0.83 | TRPV4 (0.61) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL5066101 | 0.81 | MAOB (0.49) | TRPV4MAOBMAOA | |
| SCHEMBL17201240 | 0.80 | TRPV4 (0.57) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL11959230 | 0.80 | TRPV4 (0.57) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL2538950 | 0.80 | TRPV4 (0.57) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL2389038 | 0.80 | TRPV4 (0.57) | TRPV4DAOCYP11B1CYP11B2MAOB | |
| SCHEMBL24108188 | 0.80 | CYP11B1 (0.58) | TRPV4DAOCYP11B1CYP11B2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025036382-A1 | SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海复宏汉霖生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| CN-118852176-A | Spiro compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2024-10-29 | — | — | CN | disclosed |
| WO-2000034239-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000025788-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000001701-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001382-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999009985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | TRPV4 4503/4885DAO 3337/4885CYP11B1 3814/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | TRPV4 4139/4885DAO 2354/4885CYP11B1 2896/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | TRPV4 2452/4885DAO 2393/4885CYP11B1 1047/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | TRPV4 1191/4885DAO 2925/4885CYP11B1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.